Eli Lilly Acquires Merida Biosciences for $2.88 Billion in Autoimmune Disease Expansion
Eli Lilly (LLY) has agreed to acquire privately held Merida Biosciences for up to $2.88 billion, marking its latest move into autoimmune disease research and development. The deal is part of a broader strategy by the pharmaceutical giant to diversify beyond obesity-related drugs like Mounjaro and Zepbound, which have driven much of Lilly's recent growth but also pose concentration risk as demand may wane over time. Merida’s approach focuses on targeting specific autoantibodies that cause autoimmune conditions without broadly suppressing immune function. Its lead drug candidate, MER511, is in Phase 1 trials for Graves' disease and thyroid eye disease, while another compound targets food allergies and asthma. Lilly's acquisition strategy includes milestone payments tied to clinical progress, reducing financial exposure if the science fails. Despite significant investment, investors should not expect immediate earnings impact from this deal since Merida’s drugs are still in early-stage development. Analysts view the move as a sensible use of capital that aligns with Lilly’s broader immunology expansion and long-term growth strategy.
Topics: acquisition autoimmune diseases Eli Lilly Merida Biosciences